Sartorius partners with RoosterBio to advance cell and gene therapy manufacturing
The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine
22 Jan 2021
The life science company Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media, and hMSC bioprocess systems. The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly reduce process development efforts, industrialize the supply chain and accelerate the development and commercialization of groundbreaking cell-based regenerative cures.
RoosterBio and Sartorius will create a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems, alongside Sartorius’s single use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing. Cell expansion will be rapidly optimized using Sartorius’s benchtop Ambr® system and MODDE® design of experiment software allowing the technical team to compare cultures in identically sized, multi-parallel bioreactors to gain process information and optimized conditions in a short timeline. Sartorius’s scalable Biostat STR® production bioreactors will then be used to scale up to 50L as part of this collaboration, with the system benefitting from scalability to 2000L. Sartorius equipment will also be leveraged to develop post-harvest processing methods with the kSep® system as well as process and quality analytics. This joint effort will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that can be implemented for rapid scale up of manufacturing processes, allowing product developers to significantly speed up their development timelines.
“Taking hMSC manufacturing to the thousand-liter scale is critical in meeting product dose requirements in commercial manufacturing,” said RoosterBio CEO Margot Connor. “For truly robust and standardized production in the field, a highly controlled manufacturing strategy is needed, with the implementation of automation, process monitoring and control to increase batch scale, consistency and efficiency. This collaboration is well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying foundation for true commercial scale manufacturing.”
“With the combination of technologies and tools of RoosterBio and Sartorius we support our customers to develop stem cells and therapies faster, better and more cost- efficient. Scalability is key in commercial manufacturing and this cooperation will help to meet the requirements of our customers even better”, said Hugo de Wit, Head of Advanced Therapies at Sartorius.
Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.
Do you use Sartorius products in your lab? Write a review today for your chance to win a $400 Amazon gift card>>
Related Products
Request Quote for All Products
ambr® 250 high throughput perfusion
Sartorius GroupA parallel bioreactor system for rapid development of scalable perfusion processes using 100 – 250 mL single-use bioreactors and a fully automated liquid handling platform.
BIOSTAT® CultiBag STR Plus
Sartorius GroupInnovative Bioreactor, Sensor and Stirrer Technology The BIOSTAT® CultiBag STR Plus is a stirred single use bioreactor available from small scale to large scale cultivation up to 1000L. Its design is entirely based on the conventional gold standards coming from the stainless steel systems, allowing for easy scale-up and transfer from stainless steel solutions. The BIOSTAT® CultiBag STR Plus consists of one BIOSTAT® STR Plus Control Tower, one bag holder, a single-use CultiBag STR and superior BioPAT® MFCS/DA data logging software. Single as well as twin versions are available.It is ideal for: Cell Culture applications Industrial and academic research Process development Process optimization Pilot scale production Seed cultivation for large scale bioreactors Production scale Features: Completely single use bioreactor in traditional design Top driven stirrer with magnetic coupling Application driven fully flexible gassing system Available as single and twin version User-friendly touch screen interface for easy operation Single use optical DO & pH sensors for measurement Single use bags available with working volumes of 50L, 200L, 500L and 1000L Validation & Extractible guide available
ambr® 250
Sartorius Groupambr® 250 is a new bioreactor system for parallel fermentation or cell culture using 100-250mL single-use bioreactors controlled by an automated liquid handling platform.The new system, developed with two major industrial partners, builds on the original ambr® microscale technology developed by TAP Biosystems (now part of Sartorius Stedim Biotech).